Pancreatic Neuroendocrine Tumor (pNET) research hub

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

This study compares two medicines, zanzalintinib and everolimus, for treating advanced neuroendocrine tumours. It aims to see which is more effective for people whose tumours have grown or spread despite previous treatments. This is a crucial step in finding better ways to manage this condition.